A THC pill reduced PTSD nightmares in a 10-week randomised trial
Dronabinol beat placebo on a nightmare-severity scale in 171 adults, but the effect was moderate and the only serious adverse events occurred in the drug group. Long-term safety is untested.
Dronabinol — a pharmaceutical form of THC, the main psychoactive compound in cannabis — reduced the frequency and intensity of nightmares more than placebo in a randomised trial of 171 adults with post-traumatic stress disorder [s1]. The effect was real but moderate, it was measured over only 10 weeks, and the trial's serious adverse events all occurred in the group taking the drug — so this is a promising signal that needs longer and larger testing, not a treatment ready for use [s1].
Nightmares are one of the defining features of PTSD, and the options for treating them specifically are limited [s1]. That gap is why the result is worth attention, and why the caveats around it matter just as much.
What the trial did
The study, published in Nature Medicine, was a multicentre, double-blind, randomised, placebo-controlled trial of dronabinol, referred to in the study as BX-1 [s1]. Adults with PTSD and recurrent nightmares were assigned to dronabinol at 2.5 to 15 mg or to placebo, taken once daily before bedtime for 10 weeks [s1].
In all, 171 patients were randomised — 87 to dronabinol and 84 to placebo [s1]. Their mean age was 37.9 years and 79.3% were women [s1]. The trial is registered as NCT04448808 and was sponsored by Charité University in Berlin [s2].
The primary endpoint was the change from the start of the trial to week 10 on a single, specific measure: item B2 of the Clinician-Administered PTSD Scale for DSM-IV, which rates the frequency and intensity of distressing dreams [s1]. Anchoring the trial to one clinician-rated nightmare item is a reasonable choice for a study about nightmares, but it is worth being clear that this is what "worked" refers to here — not PTSD overall.
What happened
At week 10, the reduction in the nightmare score was significantly greater with dronabinol than with placebo, a between-group difference of 1.50 points, with a 95% confidence interval from 0.71 to 2.28 and a p-value below 0.001 [s1]. The standardised effect size, Cohen's d, was 0.65 — conventionally a moderate effect [s1].
That is a clear separation from placebo on the trial's own terms. It is also a difference on a rating-scale item, and the size of it — well under two points — is the kind of change that is easier to detect statistically than to feel in a life. Whether a moderate improvement on a nightmare score translates into better sleep, less daytime distress or improved function is not something this endpoint answers.
The safety numbers are the part to read twice
Adverse events were common in both groups but more common with the drug: they occurred in 78 patients (89.7%) on dronabinol and 64 (77.1%) on placebo [s1]. Discontinuation because of adverse events was actually slightly lower on the drug — five patients (5.7%) versus six (7.2%) on placebo [s1].
The signal that deserves weight is the serious adverse events: seven (8.0%) among patients taking dronabinol, and none among those taking placebo [s1]. The trial's abstract does not detail what those events were, but an imbalance of that shape — all of the serious events on one side — is exactly what a longer, larger trial has to characterise before the benefit-risk balance can be judged. THC is a controlled psychoactive substance, and questions about tolerance, dependence, next-day impairment and effects on mood over months of nightly use are not settled by 10 weeks of data.
What it does and does not establish
The authors' conclusion is measured: the trial provides evidence that dronabinol reduces the frequency and intensity of PTSD-related nightmares, while stating plainly that long-term efficacy and safety require further evaluation [s1]. It establishes a short-term effect on a nightmare-specific measure against placebo, in a mostly female sample, over 10 weeks.
It does not establish that dronabinol improves PTSD more broadly, that the benefit lasts beyond the trial, or that the drug is safe for the extended, indefinite use that a chronic condition would imply. Nor does it compare dronabinol against the treatments already used off-label for the same problem, so where it would sit in practice is unknown.
What to watch
The obvious comparison is with prazosin, the most-studied drug for PTSD nightmares, whose evidence base is itself mixed — a head-to-head would be far more useful than another placebo trial. Dronabinol also joins a wave of drug candidates being tested for PTSD, including methylone, and it will inherit the same hard question that shadows the broader cannabinoid evidence: whether a moderate short-term effect holds up, and stays safe, over the long run of a chronic illness. The next trials, powered for durability and for those serious events, are the ones that matter.
This article describes trial results. It is not medical advice, and nothing here should be used to start, stop or change treatment.
Sources
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized placebo-controlled trial, Nature Medicine, 5 August 2026
- Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (NCT04448808), ClinicalTrials.gov
Sources
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized placebo-controlled trial — Nature Medicine , August 5, 2026
- Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol (NCT04448808) — ClinicalTrials.gov , October 1, 2020
More on
What causes nightmares in adults — and what actually helps
Nightmare disorder affects about 4% of adults. The treatment with the clearest backing is not a drug but a rehearsal technique that rewrites the dream while you are awake.
Prazosin didn't beat placebo for PTSD nightmares in its largest trial
In a 304-veteran trial, prazosin matched placebo on trauma nightmares and sleep quality. Sleep medicine's one recommended treatment for nightmare disorder is a behavioural therapy, not a drug.
Does EMDR work for PTSD? The trial evidence says yes — about as well as trauma-focused CBT
In the largest network meta-analysis, EMDR and trauma-focused CBT were the most effective treatments for adults with PTSD. The evidence is graded moderate-to-low, and the eye movements may not be why it works.
9/11's mental-health legacy: what two decades of cohort data show
Registry and responder cohorts document persistent PTSD and depression, a symptom peak more than a decade after the attacks, and a burden that compounds with chronic physical illness.